Dr. Lal PathLabs Ltd - 539524 - Announcement under Regulation 30 (LODR)-Investor Presentation
Investor Presentation for Q4 & FY 24 attached20-05-2024
20-05-2024
Dr. Lal PathLabs Ltd - 539524 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Intimation of Schedule of Analyst/ Institutional Investor Meetings17-05-2024
Dr. Lal PathLabs Ltd - 539524 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Q4 & F.Y. 2024 Earnings Call Transcript is attached15-05-2024
Dr Lal Pathlabs plans for new labs and collection centres in untouched regions
MD Om Manchanda says firm is also looking to expand further into Mumbai and select parts of Maharashtra via Suburban Diagnostics15-05-2024
Dr. Lal Pathlabs Q4 Results Review - Subdued Volume Outlook: Yes Securities
Dr. Lal Pathlabs to reinvest incremental Ebitda from operating leverage on expansion of labs which would preclude a significant improvement in margin.13-05-2024
Dr. Lal PathLabs Ltd - 539524 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Newspaper Publication attached11-05-2024
Dr. Lal PathLabs Ltd - 539524 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Disclosure Attached10-05-2024
Dr. Lal Pathlabs Results Earnings Call for Q4FY24
Conference Call with Dr. Lal Pathlabs Management and Analysts on Q4FY24 Performance and Outlook. Listen to the full earnings transcript.10-05-2024
Q4FY24 Quarterly Result Announced for Dr. Lal Pathlabs Ltd.
Healthcare Services company Dr. Lal PathLabs announced Q4FY24 results: Revenue increased by 11.1% in Q4FY24 EBITDA increased by 25.1% with a margin of 26.5% PAT increased by 50.8% with a margin for of 15.7% Result PDF10-05-2024
Dr. Lal PathLabs Ltd - 539524 - Announcement under Regulation 30 (LODR)-Investor Presentation
Revised Earnings presentation on Audited financial results for Q4 and financial year ended March 31, 202410-05-2024